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Abstract. Aquaporins are membrane proteins that regulate 
cellular water flow. Recently, aquaporins have been proposed 
as mediators of cancer cell biology. A subset of aquaporins, 
referred to as aquaglyceroporins are known to facilitate 
the transport of glycerol. The present study describes the 
effect of gene knockdown of the aquaglyceroporin AQP3 on 
MDA‑MB‑231 breast cancer cell proliferation, migration, 
invasion, adherence and response to the chemotherapeutic 
agent 5‑fluorouracil. shRNA mediated AQP3 gene knock-
down induced a 28% reduction in cellular proliferation 
(P<0.01), a 39% decrease in migration (P<0.0001), a 24% 
reduction in invasion (P<0.05) and a 25% increase in cell 
death at 100 µM 5‑FU (P<0.01). Analysis of cell permeability 
to water and glycerol revealed that MDA‑MB‑231 cells 
with knocked down AQP3 demonstrated a modest decrease 
in water permeability (17%; P<0.05) but a more marked 
decrease in glycerol permeability (77%; P<0.001). These 
results suggest that AQP3 has a role in multiple aspects of 
breast cancer cell pathophysiology and therefore represents a 
novel target for therapeutic intervention.
Introduction
Breast cancer is the leading cause of female mortality in the 
Western world (1) and is the most common form of cancer 
in the UK. One million diagnoses were made worldwide in 
2011 (2), of which over 40,000 new cases were diagnosed in 
the UK (3). Importantly, metastatic relapse is a key predictor of 
survival with fewer than 5% of women with metastatic breast 
cancer being disease free at five years (4). Although significant 
improvements in the management of primary and metastatic 
breast cancers have been made, the search for a successful and 
less toxic treatment of the metastatic breast cancer is on‑going.
The aquaporin (AQP) family of membrane protein chan-
nels facilitates rapid water transport across all cell membranes, 
thereby maintaining body water homeostasis (5). Thirteen 
human AQPs have been identified to date (6), which form two 
distinct sub‑groups: Classical AQPs (AQP0, 1, 2, 4, 5, 6 and 8) 
that solely transport water, and aquaglyceroporins (AQP3, 7, 9 
and 10) that additionally transport small, uncharged molecules 
such as glycerol and urea (6).
The aquaglyceroporin AQP3 is expressed widely in the 
body and has been implicated in an increasing number of 
physiological and pathophysiological processes. These include 
metabolism, type 2 diabetes and skin elasticity (7). AQP3‑null 
mice have also been demonstrated to have a reduced capacity 
for wound healing (8).
Recent evidence has suggested that several AQP family 
members are involved in carcinogenesis, with altered expres-
sion of AQPs being detected in several types of cancer (9). 
AQPs are now known to regulate cancer cell proliferation, 
migration, angiogenesis and metastasis (10-12). AQP3 
has further been suggested to have a role in bladder (13), 
colorectal (14), gastric (15,16), lung (17,18) and skin (19) 
cancers. In breast cancer, an increased expression of AQP3 
was reported compared to healthy border tissue, although 
the reasons for this observation are unclear (20,21). The role 
of AQP3 in breast cancer is however controversial, as recent 
evidence has suggested that AQP3 expression may be linked 
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to disease survival in HER2 positive breast cancer (22) and a 
study recently reported that AQP3 gene silencing significantly 
reduced oestradiol‑induced profilferation, invasion and migra-
tion in a cell model of breast cancer (23). It is possible that 
increased AQP3 expression in breast cancer cells may facili-
tate glycerol transport into the cell. This may then contribute 
to the generation of ATP (19), providing cancer cells with 
increased energy required for proliferation and tumouri-
genesis. Alternatively, these observations may be explained 
by as yet unassigned effects of water transport through the 
cell. Triple‑negative breast cancers are associated with poor 
survival outcomes, and have been linked to a lower 5‑year 
survival rate (24). This is due to lack of response to therapies 
such as tamoxifen and Herceptin as well as rapid tumour 
development and metastasis (25) and as such makes studying 
triple negative breast cancer a priority.
These findings suggest that AQP3 may be involved in 
several key processes that are important in breast cancer cell 
biology. In the present study AQP3 gene silencing was used to 
establish a role for this aquaglyceroporin in breast cancer cell 
pathophysiology. The effects on cellular proliferation, migra-
tion, invasion and response to a chemotherapeutic agent in the 
invasive human breast cancer cell model MDA‑MB‑231 were 
compared.
Materials and methods
Cell culture and reagents. Reagents were purchased from 
Sigma‑Aldrich (Dorset, UK) unless stated otherwise. 
MDA‑MB‑231 human breast cancer cells were purchased from 
ATCC. Cells were routinely cultured in RPMI‑1640 (PAA 
Laboratories Ltd., Somerset, UK) supplemented with 10% 
foetal bovine serum (FBS; PAA Laboratories Ltd., Somerset, 
UK), 50 IU/ml penicillin, 50 µg/ml streptomycin and 2 mM 
glutamine at 37˚C in a 5% CO2 incubator. 5‑FU was purchased 
from Tocris Bioscience (Bristol, UK).
Transfection and selection of stably expressing AQP3 shRNA 
clones. shRNA plasmids for AQP3 were purchased from 
Origene, USA. Of the four plasmid sequences, the plasmid 
that caused the most significant downregulation was chosen 
for production of stably expressing cells (termed shAQP3 
cells). Transfection of AQP3 and control shRNA plasmids 
[including a red fluorescent protein (RFP) sequence and a 
puromycin‑N‑acetyl transferase gene located downstream of 
the SV40 promoter] into MDA‑MB 231 cells was performed 
with Genjet transfection reagent (GenJet™ DNA in vitro 
Transfection Reagent; SignaGen Laboratories, Rockville, MD, 
USA). Cells were subsequently treated with 2 µg/ml puro-
mycin for 2 weeks before colonies of puromycin resistant cells 
were picked using glass colony selection cylinders. Cells then 
underwent a 5‑fold serial dilution with the last dilution being 
assessed for RFP expression and sub‑culturing.
Reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR) and western blot analysis of AQP expression. 
RNA was isolated from all samples using a proprietary RNA 
isolation kit (E.Z.N.A. ® Total RNA kit I; Omega Bio‑Tek, 
Inc., Norcross, GA, USA). Quantification of total RNA was 
performed using a Nanodrop spectrophotometer (Thermo 
Fisher Scientific, Inc., Leicester, UK). 1 µg total RNA from 
each sample was reverse transcribed using a proprietary cDNA 
synthesis kit (Primerdesign Ltd., Cambridge, UK) for 20 min 
at 55˚C. Resulting cDNA was diluted 1 in 10 and subjected to 
SYBR®‑Green Real‑Time PCR using pre‑validated sequence 
specific primers for AQPs purchased from Primerdesign Ltd. 
Housekeeping genes that were used to normalise data were 
chosen from a pool of candidate normalising genes with the 
two most stably expressed genes being employed (β-actin 
and YWHAZ). Samples were analysed using Precision 
SYBR‑Green PCR Mastermix (Primerdesign Ltd.) and a 
Stratagene MX3000P thermal cycler (Stratagene, Stockport, 
UK). Comparisons were made for each sample between the 
average crossing point (Cq) obtained from the genes of interest 
and the geometric mean of the Cq obtained from the house-
keeping genes, β‑actin and YWHAZ (giving ΔCq).
For protein analysis, cells were lysed using RIPA buffer 
(Merck Millipore, Watford, UK) and insoluble material 
removed by centrifugation at 13,000 RCF, with the insoluble 
pellet being discarded. The protein content of the lysate was 
quantified using a modified Lowry method (DC Protein 
Assay; Bio‑Rad Laboratories Ltd., Watford, UK) and photo-
metrically measured at 690 nm. All samples were compared 
to a standard curve using BSA of a known concentration. 
Briefly, for analysis of AQP3 protein expression, 60 µg 
protein per sample was denatured and separated using 
12% SDS‑PAGE. Following SDS‑PAGE, protein was trans-
ferred to a pure nitrocellulose blotting membrane (VWR 
International Ltd., Leicestershire, UK) at 100 V for 1 h and 
subsequently blocked using 5% non‑fat milk (Marvel) in 
1X TBS buffer (Sigma‑Aldrich) containing 0.1% Tween‑20 
(TBS‑T). After blocking, the membrane was washed three 
times in TBS‑T and once in TBS buffer and then incubated 
overnight at 4˚C with rabbit anti‑human AQP3 antibody (cat. 
no. sc‑20811; Santa Cruz Biotechnology, Inc., Dallas, TX, 
USA). The membrane was again washed before incubation at 
room temperature for 1 h with a goat anti‑mouse IgG‑HRP 
conjugated secondary antibody (Abcam, Cambridge, UK). 
Following secondary antibody incubation, the membrane 
was washed and subsequently exposed to the EZ‑ECL 
chemiluminescence western blotting detection system 
(Geneflow, Lichfield, UK) for 5 min. Bands were then visu-
alised using the GBOX HR 16 imaging system and GeneSys 
software (Geneflow). Blots were then stripped and probed 
for tubulin (using an anti‑tubulin antibody from Abcam; cat. 
no. ab6046) as a loading control. Band density was measured 
using ImageJ and AQP3 band density was calculated as a 
ratio of AQP3: Tubulin.
Cellular proliferation assay. All cell counts were performed 
using a Countess® Automated Cell Counter (Thermo Fisher 
Scientific, Inc.). To measure cellular proliferation, wild type 
MDA‑MB‑231 and shAQP3 cells were grown to confluence 
and serum‑starved overnight to synchronise the cell cycle. 
2x105 cells were seeded into 75 cm2 cell culture vessels 
and allowed to grow for 72 h under standard conditions. 
Cells were subsequently detached using Accutase (PAA 
Laboratories Ltd.) before being re‑counted. For each count, 
both chambers of a Countess slide were used and an average 
figure recorded.
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Cellular migration assays. Two separate methodologies were 
employed to assess cell migration. For the wound scratch 
assay (26) WT and shAQP3 cells were seeded into 6‑well 
plates, grown to confluence then serum‑starved overnight. A 
sterile 20 µl pipette tip was used to produce a cross shaped 
scratch in the middle of each well. Images were taken using a 
Leica DMI4000 B inverted microscope at time points 0, 24, 48 
and 72 h. Wound scratch analysis software TScratch was used 
to calculate the percentage wound closure for the different cell 
types at all time points (27).
Cellular migration was also assessed using a Cell‑IQ® 
automated image capture system (CM Technologies, 
Tampere, Finland). WT and shAQP3 cells were seeded into 
6‑well plates and allowed to become confluent prior to over-
night serum starvation. Cells were then scratched with a 20 µl 
pipette tip, and washed twice with HBBS to remove floating 
cells. Cells were treated with 5 µg/ml mitomycin C to inhibit 
cellular proliferation. The plates were placed on the Cell‑IQ® 
system and two regions of interest (ROI) were selected for 
each cell type. The images were obtained every 15 min 
continuously over a 24 h period. Cell migration was expressed 
as the percentage of the wound closure relative to the initial 
wound scratched area. Digitised images were then analysed 
by Cell‑IQ Analyser™ software to calculate the percentage of 
wound closure. Fig. 3C represents the mean of three separate 
experiments.
Cellular invasion assay. Cell invasion assays were carried 
out with WT and shAQP3 cells in 96‑well transwell plates 
with 8 µm pores using the Cultrex® BME Cell Invasion Assay 
system (R&D Systems Abington, UK). Cells were starved 
in serum‑free medium for 18 h before analysis. Basement 
membrane extract (BME) was used to coat transwell plates 
for 4 h at 37˚C in a CO2 incubator before being aspirated and 
50,000 cells were subsequently seeded per transwell. 10% FBS 
medium was added to the bottom chambers. Cells were incu-
bated at 37˚C in CO2 incubator for 48 h. After 24 h the top and 
bottom chambers of the invasion devices were carefully aspi-
rated, washed and Calcein‑AM (in a cell lysis buffer) was added 
to the bottom chambers and incubated at 37˚C in CO2 incu-
bator for 1 h. The top chambers were removed and plates were 
read on a SPECTRAmax® GEMINI‑XS Spectrofluorometer 
(Molecular Devices Corporation, Sunnyvale, CA, USA) at 
485 nm excitation, 520 nm emission.
Cellular adhesion assay. Wild type and shAQP3 cells 
were seeded into 96‑well plates coated with fibronectin 
(R&D Systems), where adherent cells were captured. After 4 h 
unbound cells were washed away, and the adherent cells are 
were exposed to Calcein‑AM solution before fluorescence was 
read at on a SPECTRAmax® GEMINI‑XS Spectrofluorometer 
(Molecular Devices Corporation) at 485 nm excitation, 520 nm 
emission.
Cell viability assay. For analysis of 5‑FU induced cell death, 
WT and shAQP3 cells were seeded into 96‑well plates 
at a density of 10,000 cells per well. After 48 h cells were 
treated with 5‑FU at a concentration of 100 µmol/l for 48 h. 
A proprietary resazurin‑based cell viability assay was used 
to measure induced cell death following the manufacturer's 
protocol (PrestoBlue™; Thermo Fisher Scientific, Inc.) using a 
SPECTRAmax® GEMINI‑XS Spectrofluorometer.
Fluorescent cell swelling assay. In order to assess transport 
of water and glycerol into AQP3 silenced cells, a Calcein 
AM‑based cell swelling assay was employed. Briefly, 
2.5x104 cells were seeded in triplicate in 96‑well tissue culture 
treated plates (Falcon) 24 h before the experiment. Cells were 
subsequently incubated with 5 µM calcein‑AM (Molecular 
Probes; Invitrogen Life Technologies) in complete cell culture 
media for 90 min. Excess calcein‑AM was removed by 
washing. Calcein AM fluorescence time‑series were measured 
in a BioTek Synergy HT plate reader using the 495 nm excita-
tion and 515 nm emission filters, with the internal temperature 
held at 37˚C.
For water permeability analysis fluorescence readings 
were taken every 50 ms. After 5 sec, 75 µl of hypotonic 
culture media (170 mOsm/kg H2O) was added to the 75 µl 
media (340 mOsm/kg H2O) already on the cells (to give a final 
extracellular osmolality of 255 mOsm/kg H2O; ΔOsm=85 
mOsm/kg H2O) using the plate reader injector system, at a rate 
of 350 µl/sec. Fluorescence was then measured for 49.8 sec. 
For glycerol permeability analysis, fluorescence readings 
were taken every 100 ms due to the slower rate of swelling 
associated with glycerol transport. After 10 sec, 75 µl of an 
isoosmotic (340 mM in ddH2O) glycerol solution was added 
to the 75 µl media already on the cells using the plate reader 
injector system, at a rate of 350 µl/sec. Fluorescence was then 
measured for 99.9 sec. As the glycerol solution was isoosmotic, 
any changes in cell volume could be attributed to changes in 
intracellular osmolality and subsequent osmosis due to glyc-
erol uptake. As a negative control, an isoosmotic mannitol 
solution (340 mM in ddH2O) was injected, and no change 
in fluorescence intensity was observed (data not shown). 
All solution osmolalities were measured with an Osmomat 
3000 freezing point depression osmometer (Gonotec, Berlin, 
Germany). Fluorescence readings from cells not loaded with 
calcein AM were taken as background and subtracted from 
the raw data. Data were normalised to the average of the first 
five readings after injection. Exponentially decaying growth 
curves of the form C‑Ae‑kt were fitted subject to the constraint 
C‑A=1, using the Solver tool in Microsoft Excel. Curves were 
fitted to 3 fluorescence traces per experimental repeat.
Statistical analysis. Statistical analysis of data was performed 
using GraphPad Prism 6 software (GraphPad Software, Inc., 
La Jolla,. CA, USA). One‑way analysis of variance (ANOVA) 
with Tukey's post hoc test for comparisons of ≥3 groups or 
Student's t‑test for comparisons of <3 groups were performed 
for the statistical analysis between experimental conditions. 
P<0.05 were considered significant as indicated by *; P<0.01 
are indicated by **; and P<0.001 are indicated by ***. Where 
n is stated, n refers to the number of separate biological repli-
cates assessed.
Results
AQP expression in primary human breast tissue and 
MDA‑MB‑231 cells. Expression of all 13 human AQP family 
members was investigated in the invasive breast cancer cell 
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line MDA-MB-231 using SYBR®‑Green Real‑Time PCR 
analysis. AQP3 was the most abundant transcript of all AQP 
family members, with an average Ct value of 24 (±0.89, 
Fig. 1A and B). Analysis of AQP3 gene expression in primary 
human breast tissue showed a threefold higher level of AQP3 
expression (Fig. 1C; P=0.018, n=6) in cancerous breast tissue 
compared to healthy border tissue. After shRNA‑mediated 
AQP3 gene silencing, both qPCR and western blotting (Fig. 2) 
were used to assess gene knock‑down.
Semi‑quantitative western blotting band density analysis 
demonstrated that protein expression was reduced by 60% 
(±12%) in the AQP3 shRNA stable clone (shAQP3) compared 
to WT cells (P=0.012).
shRNA‑mediated AQP3 gene silencing significantly reduces 
MDA‑MB‑231 cellular proliferation. AQP3 has been identi-
fied as a regulator of cellular proliferation in several cell 
types (8,28-30). The effect of silencing AQP3 in MDA‑MB‑231 
cells on cellular proliferation rate was measured. Analysis of 
total cell count 72 h post‑seeding showed that AQP3‑silenced 
cells (shAQP3) had a 28% reduction (±9%) in cell numbers 
compared to WT cells (P=0.01, Fig. 3). From repeated counting 
at 24, 48 and 72 h, the doubling time of cells was calculated as 
follows: WT=30.98 h, shAQP3=39.27 h (P<0.05 for shAQP3 vs. 
WT; n=8). AQP3 silencing therefore significantly decreased the 
rate of cellular proliferation in MDA‑MB231 cells resulting in 
an increased doubling time. This suggests that AQP3 is involved 
in MDA‑MB‑231 cell proliferation, and may therefore represent 
a novel target for reducing levels of breast cancer cell growth.
Silencing AQP3 mRNA causes a significant reduction in 
cellular migration. The role of AQP3 in cell migration and 
wound healing is well established (8,14,28). The present study 
therefore assessed the impact of AQP3 gene silencing of 
MDA‑MB‑231 cells, a cell line known to have migratory poten-
tial (31). In order to assess cell migration, WT and shAQP3 
cells were subjected to two assays; a wound scratch assay, an 
established measure of MDA‑MB‑231 cell migration (31,32) 
and analysis using the Cell IQ system. For the wound scratch 
assay, after 72 h, WT cells showed a wound closure of 58% 
(±6%), n=5 (Fig. 4). Wound closure was significantly reduced 
in the shAQP3 cells to just 25% (±6%; P=0.001). Using the 
Cell IQ system, in conjunction with mytomycin C treatment 
to inhibit cellular proliferation, shAQP3 cells showed a 39% 
reduction in cellular migration after 24 h compared to WT 
cells. These data demonstrate that AQP3 is an important regu-
lator of MDA‑MB‑231 cell migration, and that cell migration 
can be potently inhibited in vitro by targeting AQP3 expres-
sion. As mytomycin C, a mitotic inhibitor, was used for the 
CellIQ assay these results suggest that the difference in wound 
closure observed was not due to the effects of AQP3 silencing 
on proliferation.
Stable AQP3‑silenced cells show decreased levels of cellular 
invasion but unchanged cellular adhesion. The process of 
metastasis, the spread of cancer cells from a primary site to 
distant parts of the body, is initiated by cellular invasion and is 
considered a pivotal aspect of cancer mortality (33). In order 
to assess the levels of invasiveness of cells in which AQP3 had 
been silenced, proprietary BME‑ and collagen‑based cellular 
invasion assays was used, whereby cells were challenged using 
BME or collagen coated transwell dishes through which they 
were required to invade in order to reach a bottom chamber. 
After a 72 h incubation period, shAQP3 cells showed a signifi-
cantly reduced level of invasion through BME‑ and collagen 
coated plates of 76% (±3%) and 77% (±4%) respectively 
compared to WT cells (Fig. 5A and B, n=6).
Cellular adhesion plays an important part in cancer 
progression and metastasis (34) with circulating cancer 
cells ultimately interacting with endothelial cells, leading to 
extravasation (35). WT and shAQP3 cells were seeded into 
fibronectin coated plates for 4 h to assess levels of cellular 
adhesiveness. Analysis of Calcein‑AM staining in each well 
after this period showed that there was no significant difference 
in the levels of cellular adhesion between the two cell types 
Figure 1. AQP gene expression in breast cancer biopsies and MDA‑MB‑231 
cells. (A) qPCR analysis of AQP family mRNA expression in breast cancer 
biopsy samples. Data expressed as mean Cq value ± SEM (n=8). (B) Graphical 
representation of qPCR expression in MDA‑MB‑231 cells with all AQPs 
normalised to the expression level of AQP0. Bars represent mean ± SEM. 
(C) qPCR analysis of AQP3 mRNA expression in primary healthy breast 
tissue (HBT) and matched cancerous tissue (CT). Bars represent mean expres-
sion levels normalised to HBT (n=6). *P<0.05 vs. HBT.
Figure 2. AQP expression after shRNA‑mediated gene‑silencing in 
MDA‑MB‑231 cells. (A) qPCR analysis of AQP3 mRNA expression levels 
in stably shRNA transfected MDA‑MB‑231 cells (shAQP3) compared to 
wild type (WT) cells (n=8). (B) AQP3 protein expression in shAQP3 cells 
measured by semi‑quantitative western blotting, (n=6). *P<0.05. Bars repre-
sent mean ± SEM.
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(P=0.56, Fig. 5C; n=8) suggesting that AQP3 does not have a 
role in MDA‑MB‑231 cell adhesion.
AQP3 silencing increases 5‑FU induced cell death. 5‑FU is 
a fluoropyrimidine pro‑drug commonly given to treat bowel, 
breast or stomach cancer (36). A regulatory role for AQP3 
in chemotherapy‑induced breast cancer cell death has previ-
ously been suggested (20). We therefore investigated the role 
of AQP3 in cell death by exposing WT and shAQP3 cells to 
a range of 5‑FU concentrations for 48 h and subsequently 
measuring cell viability. shAQP3 cells showed significantly 
lower (maximal 25% reduction, P<0.05; n=5) levels of cell 
viability at all 5‑FU concentrations tested when compared to 
WT cells (Fig. 6), suggesting that AQP3 has a cytoprotective 
effect in breast cancer cells.
AQP3 silencing markedly decreases glycerol permeability in 
MDA‑MB‑231 cells. As AQP3 is known to be permeable to 
both water and glycerol, analysis of the transport of both of 
these molecules was performed in WT and shAQP3 cells to 
provide information regarding the likely role of AQP3 in these 
cells. Analysis of cellular fluorescence using cells pre‑exposed 
to calcein AM (adapted from (37)) showed that shAQP3 cells 
displayed a significant decrease of 17% in cellular permeability 
to water (P=0.016, n=3) compared to control cells (Fig. 7). There 
was however a more marked decrease in glycerol permeability 
in shAQP3 cells (Fig. 8), with a 77% decrease in glycerol perme-
ability being observed (P=0.0018, n=3) compared to control 
cells, suggesting that AQP3 in MDA‑MB‑231 is preferentially 
Figure 4. AQP3 silenced cells exhibit reduced migration rate. Analysis of 
cellular migration using the CellIQ imaging and automated analysis system 
after 24 h (n=3). Data represents mean ± SD. ***P<0.0001.
Figure 3. Reducing AQP3 expression inhibits cellular proliferation rate. Cell 
viability assay comparing stable AQP3 knock‑down MDA‑MB‑231 cells 
(shAQP3) with WT at 24, 48 and 72 h (n=8). **P<0.01 vs. shAQP3. Data 
points represent mean ± SEM.
Figure 5. AQP3 mediates cellular invasion but not adhesion. Graphical 
representation of the relative level of shAQP3 and wild type (WT) inva-
sion through (A) BME substrate and (B) collagen substrate after 24 h. n=8. 
**P<0.01. (C) Cellular adhesion of shAQP3 and WT cells as measured by 
calcein AM fluorescence after 4 h incubation in fibronectin coated plate. n=8. 
Bars represents mean ± SEM.
Figure 6. AQP3 gene silencing sensitises MDA‑MB‑231 cells to 5‑fluo-
uracil‑induced cell death. Cell viability assay comparing shAQP3 cells 
and wild type (WT) exposed to 5FU after 48 h (n=6). Black bars=WT, 
open bars=shAQP3. *P<0.05, **P<0.01, ***P<0.001 vs. WT. Bars represent 
mean ± SEM.
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a glycerol channel and that the effects of AQP3 silencing are 
likely due to a reduction in glycerol transport.
Discussion
The rates of breast cancer remain high in most societies, as do 
the mortality‑incidence ratios (38). With this in mind, identi-
fication of novel cellular targets for therapeutic interventions 
is of key importance for developing the repertoire available 
to clinicians. It is known from previous work that AQP3 is 
expressed in most epithelia (39) and that expression levels are 
significantly upregulated in cancerous breast epithelia (40). 
In addition, previous studies have suggested that AQP3 is 
involved in oestrogen‑induced breast cancer cell migration, 
invasion and proliferation (23). This study reports for the first 
time that downregulation of AQP3 expression in breast cancer 
cells significantly modulates several clinically relevant aspects 
of breast cancer cell biology.
A key finding presented here is that silencing AQP3 expres-
sion produced a marked reduction in cellular proliferation rate 
(leading to an increase in the doubling time) in MDA‑MB‑231 
cells. Previous evidence suggests that AQP3 is involved in 
epithelial cell proliferation (29), although no evidence of this 
effect in breast epithelial cells has previously been reported. 
Targeting the proliferation rate of cancerous breast epithelial 
cells is of great importance as cellular proliferation (measured 
by Ki67 expression or mitosis counting) has been significantly 
correlated with disease prognosis in numerous studies (41,42). 
These data, in combination with the findings presented here, 
suggest that targeting cellular proliferation by pharmaceutical 
downregulation or inhibition of AQP3 expression or function 
is clinically relevant and might be associated with a better 
prognosis.
We can also report here that knockdown of AQP3 in 
MDA‑MB‑231 cells resulted in significant decreases in cellular 
migration and invasion and that these effects are in addition 
to the effects on proliferation. Recent data have shown that 
AQP3 is necessary for fibroblast growth factor‑2 induced cell 
migration in MDA-MB-231 cells (43), suggesting that AQP3 is 
a key regulator of migration in these cells. These observations 
are of key importance as they suggest that targeted reduction 
in AQP3 levels may not only inhibit the ability of tumour cells 
to proliferate, but also reduce the ability of breast cancer cells 
to break through a basement membrane and spread to distant 
sites. Axillary lymph node metastases remains an important 
prognostic factor for breast cancer, and therefore any interven-
tion that can reduce the capacity of primary breast cancer cells 
to spread to distant sites is of significant clinical interest.
The mechanism by which AQP3 may influence cellular 
migration is not known. It has been previously demonstrated 
that AQP3 mediated H2O2 transport, and that this has a poten-
tial role in the regulation of breast cancer cell migration (44). 
Our data show that glycerol permeability is significantly 
reduced in shAQP3 cells and this reduction is markedly 
more than that seen for water permeability (Figs. 7 and 8). 
Whilst this is not mechanistic proof, glycerol transport and 
possibly its role in cell metabolism may be the mechanism by 
which reducing AQP3 expression leads to changes in cellular 
behaviour.
AQP3 represents an exciting target for breast cancer 
therapy as it fulfils several criteria. First, it is a membrane 
protein and therefore relatively accessible using traditional 
pharmaceutical means (45). Secondly, research using AQP3 
knockout mice has shown that the only major phenotypic 
consequences of global AQP3 knockdown are limited to dry 
skin and reduced wound healing (46-48); although a delay in 
wound healing is potentially an issue post‑operatively, this 
can hypothetically be overcome by delaying any AQP3‑based 
Figure 7. AQP3 gene silencing induces a small decrease in water transport. 
Representative calcein AM fluorescence intensity time‑series of (A) WT 
and (B) shAQP3 cells subjected to a 85 mOsm inwardly directed osmotic 
gradient (black), and fitted exponential decay function of the form C‑Ae‑kt 
(red). (C) Osmotic water permeability of WT and shAQP3 cells normalised 
to the average wild type permeability. n=3, with each n an average over 3 
fluorescence time‑series. *P<0.05. Bars represent mean ± SEM.
Figure 8. AQP3 gene silencing induces a marked decrease in glycerol trans-
port. Representative calcein fluorescence intensity time‑series of (A) WT 
and (B) shAQP3 cells subjected to a 170 mM inwardly directed glycerol 
gradient (black), and fitted exponential decay function of the form C‑Ae‑kt 
(red). (C) Glycerol permeability of WT and shAQP3 cells normalised to the 
average wild type permeability. n=3, with each N an average over 3 fluores-
cence time‑series. ***P<0.001. Bars represent mean ± SEM.
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therapy after wound closure is complete. These observations 
suggest that there may be only limited consequences from 
using a global approach to reducing either AQP3 expression 
or function in breast epithelial cells. The lack of potential side 
effects that might be associated with global AQP3 knockdown 
is therefore a key strength of using AQP3 as a target for novel 
therapeutic interventions. This study provides a platform for 
further work; it would be beneficial to compare the effects of 
AQP3 in primary breast cancer epithelial cells and a range of 
other breast cancer cell models (including hormone‑sensitive 
cell lines) as part of a wider programme for the translational 
impact of this study.
In conclusion, this study reports that AQP3 downregula-
tion reduces breast cancer cell proliferation, migration and 
invasion in MDA‑MB‑231 cells whilst increasing sensitivity to 
the antimetabolite chemotherapy drug, 5‑FU. This is the first 
study to identify AQP3 as a target for breast cancer therapy.
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